We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Transcription Factor Genes Kill Tumors

By Biotechdaily staff writers
Posted on 15 Feb 2005
Cancer researchers working with a rodent model for prostate cancer have used an adenovirus vector to implant the genes for two transcription factors, PEA-3 and AP-1, which selectively activated a tumor-suppressing gene and eradicated the cancer cells without harming normal tissues.

Investigators at Columbia University Medical Center (New York, NY, USA) created an adenovirus vector containing the genes for the transcription factors PEA-3 and AP-1. More...
These factors were known to trigger the conversion of inactive PROM-PEG cancer protein into active PEG-3 (progression-elevated gene-3), an apoptosis initiator. PROM-PEG is generally found in abundance in cancer cells but is not present in normal cells.

Results published in the January 25, 2005, issue of the Proceedings of the [U.S.] National Academy of Sciences revealed that tumors in mice receiving the vector died while normal tissues were not affected. The PEA-1/AP-1 combination was also found to act on melanoma, ovarian, breast, and glioma (brain) tumors.

"What is exciting is we may now be able to design a therapy that will seek out and destroy only cancer cells,” said senior author, Dr. Paul B. Fisher, professor of clinical pathology at Columbia University Medical Center. "We hope it will be particularly powerful in eradicating metastases that we cannot see and that cannot be eliminated by surgery or radiation. Gene therapy, especially for cancer, is really starting to make a comeback.”






Related Links:
Columbia University Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.